Oncology

Discovery
IND-enabling
Phase 1
Phase 2
Phase 3
Trifecta MEK

Title

10%
KRAS4B

Title

10%
RAS induction

Title

10%
Covalent-MEK

Title

10%
PI3K-alpha

Title

10%

Neuroscience

IMM-ALL-01

Title

8%
IMM-ALL-03

Title

8%

More than half of all tumors rely on inappropriate activation of the RAS/RAF/MEK pathway, yet existing drugs targeting this pathway are limited by toxicity or are narrowly focused on subpopulations with specific mutations. Immuneering’s novel drug candidates spare healthy normal cells by modulating cell signaling dynamics to selectively impact tumor cells.

Oncology – Select Therapies

IMM-1-104

IMM-1-104 aims to achieve pan-RAS activity that selectively impacts cancer cells to a greater extent than healthy cells. It is designed to be a highly selective third generation MEK inhibitor that modulates the signaling dynamics of the MAPK pathway by driving deep cyclic inhibition that deprives tumor cells of the sustained proliferative signaling required for rapid growth, while providing a cadenced, normalized level of signaling designed to spare healthy cells. IMM-1-104 is being developed to treat advanced solid tumors in patients harboring RAS mutations. The IMM-1-104 Phase 1/2a clinical trial is now recruiting (NCT05585320) 

IMM-6-415

IMM-6-415 targets RAF and RAS mutant tumors through deep cyclic inhibition of the MAPK pathway with an accelerated cadence. IMM-6-415 was designed with unique drug-like properties that distinguish it from other programs in the Immuneering pipeline, including a substantially shorter half-life than IMM-1-104 which gives IMM-6-415 an accelerated cadence relative to the once-daily dosing of IMM-1-104. IMM-6-415 is being developed for monotherapy and combination applications in oncology, including the ability to enhance immune mediated therapy in certain settings. 

Alzheimer’s

For most Alzheimer’s patients, there is no clear trajectory of disease progression or worsening symptoms. In fact, even clinical presentation can be widely different from individual to individual, suggesting that Alzheimer’s is less of a disease and more of a syndrome. Integrating brain gene expression and Alzheimer’s marker data offers the potential to stratify patients into subgroups with unique biology and identify targets specific to these subgroups. We aim to be leaders in delivering effective precision medicines to patients suffering with Alzheimer’s disease globally.